FDA Accepted New Drug Application for Fenebrutinib
The FDA granted priority review to the application for fenebrutinib, a potential new treatment for multiple sclerosis.
Updated on Sept. 30, 2026 in Stroke
Live Poll
Do you trust that new high-efficacy drugs will improve long-term outcomes for chronic disease patients?
The FDA has accepted the New Drug Application for fenebrutinib, an investigational Bruton's tyrosine kinase inhibitor developed to treat multiple sclerosis. If approved, the medication could become the first therapy to address both relapsing and primary progressive forms of the disease.
Why it matters
Fenebrutinib is designed to target both acute inflammation that causes relapses and chronic inflammation that drives disability progression. By inhibiting B cells and crossing the blood-brain barrier to reach microglia, it offers a dual approach to managing the condition.
The clinical program for fenebrutinib includes a safety database of more than 2,700 participants. The studies showed a 51.1% annualized relapse rate reduction versus teriflunomide and a 12% reduction in disability progression risk versus ocrelizumab.
The players
FDA
The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs.
Roche
Roche is a multinational healthcare company headquartered in Basel, Switzerland, that focuses on pharmaceuticals and diagnostics research.
The details
Fenebrutinib acts as a non-covalent Bruton's tyrosine kinase inhibitor that modulates the immune system to mitigate disease activity. It is being studied for its potential to improve outcomes for the estimated 1 million Americans currently living with multiple sclerosis.
Timeline
February 7, 2026: Results were presented at the ACTRIMS Forum 2026.
April 21, 2026: Findings were presented at the AAN Annual Meeting.
September 30, 2026: The FDA officially accepted the New Drug Application.
The Big Picture
The FDA submission follows data generated by the FENhance and FENtrepid clinical trial programs. This milestone represents a critical advancement in the evaluation of Bruton's tyrosine kinase inhibitors for neurological treatment.
If approved, this therapy could provide a new, targeted treatment option for patients managing chronic disability progression alongside relapses. Patients should consult their neurologists regarding current clinical trial availability and future medication options.
The takeaway
This regulatory update marks a significant step toward potential new standards of care for millions affected by multiple sclerosis. Patients and providers should monitor official health communications for updates on the review timeline.
Further reading
Learn more about the latest developments in neurological care at the Stroke section.
More information
Find further details regarding clinical development programs on the Roche corporate information portal.
Live Poll
Do you trust that new high-efficacy drugs will improve long-term outcomes for chronic disease patients?
